

1 **Full Title: Dietary Assessment and Prevention of Hypertension in Nigeria: Protocol for**
2 **a Retrospective Cross-sectional Study for the Development and Validation of a Food**
3 **Frequency Questionnaire for Clinical Use.**

4
5 **Short Title: Dietary Assessment and Hypertension Prevention in Nigeria: FFQ**
6 **Development & Validation**

7
8 **Authors:**

9 **Nimisoere P. Batubo, J. Bernadette Moore, and Michael A. Zulyniak**

10

11 **Affiliates:** Nutritional Epidemiology Group, School of Food Science and Nutrition,
12 University of Leeds, Leeds, LS2 9JT.

13

14 **Corresponding author:**

15 Dr Michael A. Zulyniak,

16 School of Food Science and Nutrition, University of Leeds, Leeds, LS2 9JT.

17 Email: m.a.zulyniak@leeds.ac.uk; Ph. +44(0)1133430685

18

19 **Trial registration:** *ClinicalTrials.gov*: NCT05973760. Registered August 3rd, 2023

20

21 **Protocol version:** Version 1

22

23 **Funding:** This study was funded by the Tertiary Education Trust Fund (TETFund) of
24 Nigeria. MAZ is currently funded by Wellcome Trust (217446/Z/19/Z). The funders do not
25 have any role in any aspect of this study.

26

27 **Competing interests:** There are no conflicts of interest.

28

29 **Roles and Responsibilities Authors:** NPB wrote and drafted the protocol, while NPB and
30 MAZ collaborated on the research methodology design. JBM and MAZ played significant
31 roles in reviewing and revising the protocol.

32

33

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

34 **Abstract**

35 **Introduction:** Contrary to North America and Europe, the prevalence of hypertension is rising
36 in West Africa. With a transition from whole foods to processed foods in Nigeria, diet plays a
37 key driver of hypertension. To combat this, the national nutritional guidelines in Nigeria were
38 implemented, but their translation into actionable tools for clinicians remains a challenge.
39 Currently, there are no simple dietary assessment tools that are concise and suitable to be
40 incorporated into clinical care without requiring extensive data analysis while still providing
41 personalised dietary support to their patients. This study aims to deliver a clinically tested and
42 validated short dietary assessment tool for clinicians, patients, and researchers across Nigeria
43 to provide personalised dietary advice for patients with hypertension.

44

45 **Methods:** The study will be conducted in two phases: Phase 1 (n=75) will investigate the
46 feasibility of the short FFQ and its agreement with 24-hour dietary recalls (3x) in a clinical
47 setting in Nigeria. During the analysis of Phase 1 data, a scoring system will be developed
48 based on the associations between individual food items in the FFQ and measures of
49 hypertension. Phase 2 (n=50) will assess the acceptability of the FFQ and validate the
50 association between the FFQ score and hypertension.

51 **Expected outcomes:** The development of a clinically tested and validated short food frequency
52 questionnaire that will be ready to use by clinicians, patients, and researchers across Nigeria to
53 support the prevention and management of hypertension.

54

55 **Conclusion:** This study will contribute to knowledge on dietary assessment and hypertension
56 prevention by developing a validated and acceptable FFQ, which will be valuable for clinicians
57 and researchers for personalised dietary recommendations to combat hypertension in Nigeria.

58 **Keywords:** West Africa, diet, food, LMIC, blood pressure.

59 1. Introduction

60 1.1. Background and Rationale

61 Hypertension, defined as sustained high blood pressure, is the leading preventable risk factor
62 for cardiovascular disease and the number one cause of death globally (1). Approximately 40%
63 of people aged 30-79 years have hypertension, with two-thirds of cases living in low- and
64 middle-income countries, including African countries (2, 3). The most recent data from the
65 World Health Organisation (WHO) show that the African region has the highest prevalence of
66 hypertension (35.5%), with the Americas having the lowest (18%) (4). Countries such as the
67 UK, the US, and China have seen a decrease in the prevalence of hypertension, with rates
68 declining by 6.25%, 11.38%, and 16.3%, respectively, from 2010 to 2019 (5-7). On the
69 contrary, West African countries like Nigeria have shown a consistent increase in the
70 prevalence of hypertension during this same time period. The most recent data estimate a
71 15.3% increase in hypertension rates in Nigeria from 2010 to 2019 [4,8], which has directly
72 led to a documented increase in the prevalence of heart disease, stroke, and chronic kidney
73 disease [9,10].

74

75 The increase in hypertension rates in West African countries has been attributed to unhealthy
76 dietary practices and a lack of physical activity (1, 8). Among Nigerians, there has been a
77 notable shift in dietary habits, with a significant rise in meals consumed outside the home and
78 a growing preference for fast-food establishments offering processed foods high in fat, salt,
79 and sugar (9). Unfortunately, this dietary transition has led to a surge in overweight, obesity,
80 and the prevalence of diet-related non-communicable diseases, including hypertension,
81 hypercholesterolemia, and diabetes (9). National nutritional guidelines were implemented in
82 Nigeria in October 2014, providing evidence-based recommendations to reduce the risk of
83 NCDs such as hypertension, diabetes, and obesity (10). However, the translation of these

84 guidelines into actionable advice for clinicians for combating hypertension has been a
85 challenge, possibly because (i) clinicians in Nigeria have not been provided with an effective
86 strategy to provide regionally-specific dietary information to their patients, and (ii) the
87 evidence used to inform Nigeria nutritional recommendations is based on evidence weighted
88 towards non-Nigerian studies which may not be translatable or applicable to manage the
89 contribution of diet towards the rising trend of hypertension risk in Nigeria and other West
90 African countries.

91

92 Dietary assessment methods such as diet records and 24-hour dietary recalls are commonly
93 used to evaluate an individual's typical food and nutrient intake (11). However, these methods
94 can be time-consuming and impractical in clinical settings (12). Alternatively, a brief food
95 frequency questionnaire (FFQ) offers a more convenient and cost-effective approach to assess
96 individual usual dietary intake and adherence to specific dietary patterns (12, 13). Nonetheless,
97 effective dietary counselling requires a patient-centred approach that demands both time and
98 expertise (14), making it challenging for clinicians and other health professionals to implement
99 the use of dietary assessment tools in clinical care. Currently, there are no simple dietary
100 assessment tools suitable for use by clinicians and healthcare professionals in clinical practice
101 in Nigeria that are concise enough to be incorporated into clinical care without requiring
102 extensive data analysis while still providing personalised dietary support to their patients. To
103 overcome this gap, the study has set the following objectives: (1) to investigate the feasibility
104 of a dietary assessment tool (FFQ) and its agreement with 24-hour dietary recalls (24HR) in a
105 clinical setting in Nigeria and to develop a scoring system for the FFQ, and (2) to evaluate the
106 acceptability of the FFQ and the association between the FFQ score and hypertension risk in
107 Nigeria.

108

109 1.2. Study Aims and Objectives

110 1.2.1. Study Aims

111 The overall aim is to deliver a clinically tested and validated short dietary assessment tool that
112 will be ready to use by clinicians, patients, and researchers across Nigeria to provide
113 personalised dietary advice to patients with hypertension and empower its citizens to improve
114 their diet and take an active role in hypertension prevention.

115

116 1.2.2. Study Objectives

- 117 1. To assess the feasibility of implementing the FFQ in a clinical setting in Nigeria.
- 118 2. To examine the agreement between the FFQ and 24-hour dietary recalls in capturing
119 dietary information.
- 120 3. To develop a scoring system for the FFQ based on the associations between individual
121 foods and continuous measures of hypertension (Blood pressure).
- 122 4. To evaluate the acceptability of the FFQ among the study participants.
- 123 5. To assess the association between the FFQ score and hypertension.

124

125 1.3. Trial design

126 This study will adopt a monocentric, retrospective, cross-sectional, controlled, open-label,
127 nonrandomised design with parallel branches that will be conducted in a clinical setting at
128 Rivers State University Teaching Hospital, Port Harcourt, Rivers State, Nigeria. The trial will
129 adhere to the SPIRIT guidelines for effective scheduling and time management of trial
130 participants (**Figure 1**). The study will be conducted in two distinct phases. Phase 1 will
131 investigate the feasibility of the FFQ and its agreement with 24-hour dietary recalls, while
132 Phase 2 will assess the acceptability of the FFQ and validate the association between the FFQ
133 score and hypertension (**Figure 2**). Ethical approval has been granted by the University of
134 Leeds, UK (AREA FREC 2023-0484-572) and Rivers State University Teaching Hospital,
135 Nigeria (RSUTH/REC/2023316).

136

137 2. Methods

138 2.1. Participants, Interventions and Outcomes

139 2.1.1. Study setting

140 The study will take place at the Rivers State University Teaching Hospital in Port Harcourt,
141 Nigeria. This clinical setting was chosen due to its accessibility to patients and well-established
142 medical care and research infrastructure.

143

144 2.1.2. Eligibility criteria

145 Interested individuals will be screened for eligibility during their regular clinical appointments,
146 where clinicians, nurses, and the research team will use a short questionnaire to evaluate if they
147 meet the inclusion of the study (**Table 1**).

148 **Table 1:** Eligibility criteria for the recruitment of study participants (clinical patients)

Inclusion criteria	Exclusion criteria
Age between 18 and 70 years Men and women	Individuals < 18 years or > 70 years of age Pregnant women or intent to become pregnant Breastfeeding woman
Hypertensive or non-hypertensive individual Individuals resident in Nigeria for the past 2 years.	Diagnosis of other chronic diseases such as cancer, diabetes, renal failure, or endocrine diseases, and previous and recent cardiovascular disease (CVD) and stroke.
Ability to read, write, and communicate over the phone in English Individuals who gave their consent to participate.	Individuals on dietary restriction or recent changes to their diet or food Individuals who are currently enrolled in other studies

149

150 2.1.3. Intervention

151 **Food Frequency Questionnaire (FFQ):** Food frequency data will be collected using the pre-
152 printed self-administered food frequency questionnaire of 27 main food groups. For each food
153 item, participants will be asked to report how many times they consumed the food over the past

154 week (times/week). The FFQ will be self-administered to the participants in the clinics during
155 their clinic appointment on the first and third visits.

156

157 **24-Hour dietary recall (24HR):** A 24-hour dietary recall (24HR) will be used to capture the
158 habitual consumption of foods among the participants (15) and used as the reference method
159 to validate the FFQ. The 24HR will be used to collect dietary information of the participants in
160 the past 24 hours using the multiple-pass method (16, 17).

161

162 **2.1.4. Outcomes**

163 **Primary Outcome Measures**

164 The primary outcome of this study is to deliver a clinically tested and validated short dietary
165 assessment tool (FFQ) that will be shared with Nigerian Health Authorities and experts for
166 implementation into Nigerian clinical practice. While this tool alone will not eliminate
167 unhealthy diet and hypertension risk, it will be a major step towards positioning ‘diet’ as a
168 practical means of hypertension prevention in Nigeria. This analysis of the result of the study
169 will include descriptive data related to assessing the feasibility, validity, and reproducibility of
170 the FFQ designed for the dietary evaluation and prevention of hypertension in Nigeria. On
171 assessing the feasibility of the FFQ, gauging participants' perceptions of clarity, ease of use,
172 cultural appropriateness, and encountered difficulties while completing the questionnaire.

173

174 **Secondary Outcome Measures**

175 Secondary outcomes will evaluate the agreement between FFQ and 24-hour dietary recalls
176 (24HR) in assessing dietary intake, using correlation coefficients to establish consistency
177 between methods. Additionally, we seek to explore the association between FFQ scores and
178 hypertension risk, quantifying the odds ratio that reflects the odds of hypertension about the

179 FFQ scores. Furthermore, we will assess the acceptability of the FFQ through participant-
180 reported feedback, providing insights into the practicality and user-friendliness of the tool.

181

182 **2.1.5. Participant timeline**

183 The participant timeline and schedule of enrolment, interventions, assessments, and visits for
184 participants are outlined in **Figure 1** in accordance with SPIRIT guidelines. During Phase 1, a
185 one-month recruitment period will be initiated to identify clinical patients meeting the
186 eligibility criteria. These patients will be approached for informed consent and subsequently
187 categorised into two groups based on their history of hypertension. Participants will undergo
188 comprehensive baseline assessments in the initial week of their clinical appointments. These
189 assessments will encompass the administration of the Food Frequency Questionnaire (FFQ)
190 and the First 24-hour dietary recall (24HR). The participant's blood pressure and essential
191 anthropometric measurements, including height and weight, will also be recorded. Moreover,
192 demographic and health status information will be collected to overview the participants'
193 profiles comprehensively. A second 24-hour dietary recall assessment will be conducted in the
194 subsequent weeks, followed by a final set of assessments in the third week post-allocation.
195 These final assessments will include the administration of the second FFQ, the third 24-hour
196 dietary recall (24HR), and recording blood pressure, height, and weight measurements.

197

198 Phase 2 of the study will involve participants who have provided informed consent. Over four
199 weeks, participants will undergo assessments during their clinical appointments. Central to this
200 phase is the refined FFQ-based dietary intake evaluation, designed to capture detailed
201 information on participants' dietary habits. Simultaneously, height and weight measurements
202 will be taken to ensure accurate and up-to-date anthropometric data. Additionally, relevant
203 demographic and health status information will continue to be collected, allowing for a

204 comprehensive understanding of participants' backgrounds and overall health profiles. This
 205 phase provides a detailed and in-depth analysis of participants' dietary habits and their potential
 206 correlation with hypertension status.

Study Period for Phase 1 Activity/Assessment			Feasibility, Reproducibility & Validation					
			Enrolment	Allocation	Post-allocation			Close-out
Pre-screening Consent	Staff Member	Time to complete	$-t_1$	0	t_1	t_2	t_3	t_x
			Pre-study Screening/ consent	Pre-study Baseline/ randomisation	Study Visit 1	Study Visit 2	Study Visit 3	
Screening/ Inclusion and Exclusion form	Clinicians/ Study coordinator	5 minutes	x					
Participants information sheet (PIS)	Study coordinator	72 hours	x					
Consent Form	Study coordinator	5 minutes	x					
Allocation in Groups	Study coordinator	5 minutes		x				
Demographic and Health Questionnaire	Interviewer	5 minutes		x				
BP, Height, and Weight measurement	Interviewer	10 minutes		x			x	
FFQ-1 + First 24- HR	Interviewer	25 minutes			x			
Second 24-HR	Interviewer	15 minutes				x		
FFQ-2 + Third 24- HR	Interviewer	25 minutes					x	
Final data verification	Interviewer	10 minutes						x
Study Period for Phase 2 Activity/Assessment			Acceptability and Agreement Between FFQ Score and Blood Pressure.					
			Enrolment	Allocation	Post-Allocation		Close-out	
Pre-screening Consent	Staff Member	Time to complete	$-t_1$	0	t_1		t_x	
			Pre-study Screening/ consent	Pre-study Baseline/ randomisation	Study Visit 1			
Screening/ Inclusion and Exclusion form	Clinicians/ Study coordinator	5 minutes	x					
Participants information sheet (PIS)	Study coordinator	72 hours	x					
Consent Form	Study coordinator	5 minutes	x					
Allocation in Groups	Study coordinator	5 minutes		x				
Demographic and Health Questionnaire	Interviewer	5 minutes		x				
BP, Height, and Weight measurement	Interviewer	10 minutes		x				
Refined FFQ	Interviewer	10 minutes			x			
Final data verification	Interviewer	10 minutes					x	

207
 208 **Figure 1:** Schedule of enrolment, interventions, and assessments in accordance with the
 209 SPIRIT guidelines. t_1 : week 1; t_2 : between week 1 and 3, t_3 : Week 3, t_x : post-week 3

210 **2.1.6. Sample size and sampling technique**

211 A non-probability convenience sampling method will be used to recruit eligible participants
212 from the outpatient clinics at Rivers State University Teaching Hospital (RSUTH). Previous
213 studies examining the correlation between food frequency questionnaire (FFQ) and 24-hour
214 dietary recall have found a strong agreement with correlation coefficients (r) ranging from 0.3-
215 0.7 (18-21). Based on this, a modest $r = 0.5$ is considered a good indicator for determining
216 the sample size needed to evaluate the agreement between our clinical FFQ and 24-hour recall
217 (22). For phases 1 and 2 of the study, a statistical power of $P = 0.8$, a 95% confidence interval,
218 and a two-tailed alpha level of 0.05 were chosen. Using G*Power software (23) to estimate the
219 required sample size based on the correlation coefficient ($r=0.5$), it was determined that a
220 minimum sample size of 29 participants would be needed. In addition, recent evidence suggests
221 that 13 participants are adequate to achieve sufficient qualitative feedback (i.e., saturation) in
222 studies with a small number of clear objectives (*See Section 3.4.2: Feasibility assessment of*
223 *FFQ*) (24). As such, we will also be sufficiently powered to evaluate the qualitative evidence
224 and feedback with 29 participants. Nonetheless, to account for an anticipated dropout rate of
225 20% and to accommodate any potential missing/incomplete data, the target sample size will be
226 set to 50 participants (**Figure 2**) (25, 26). Therefore, a sample size of 50 participants (clinical
227 patients) will be deemed sufficient to achieve saturation for the feasibility, validation, and
228 acceptability goals in phases 1 and 2 of the study. In addition, we will aim to recruit 25 clinical
229 healthcare professionals (i.e., nurses and clinicians) at RSUTH to provide qualitative feedback
230 on the questionnaire.

231

232 **2.1.7. Recruitment**

233 The study participants will be adult clinical patients and will be recruited from the Rivers State
234 University Teaching Hospital (RSUTH) outpatient clinics in Port Harcourt, Rivers State,

235 Nigeria. The recruitment methods for phases 1 and 2 of this study will involve a multifaceted
236 approach. Participants (clinical patients) will be recruited through recruitment posters
237 displayed in key hospital areas, clinician referrals, and engaging discussions during morning
238 briefing sessions where vital signs are taken from clinical patients in internal medicine and
239 family medicine departments. The healthcare professionals will identify eligible participants
240 based on study criteria, and informational posters will provide essential study details and refer
241 interested participants to the study team for further screening.


242

243 **2.2. Assignment of Interventions**

244 Participants in this study will be allocated into non-hypertensive and hypertensive groups based
245 on their history of hypertension, as illustrated in **Figure 2**. Allocation will be conducted
246 following predefined criteria and without randomisation. The implementation of group
247 allocation will be carried out by the primary investigator based on the predetermined criteria.
248 Participants will not be informed of their assigned group during their respective clinic
249 appointments. Allocation will be conducted in a standardised and systematic manner to uphold
250 the integrity of the study.

251

252



253

254 **Figure 2.** Participant selection and sequence of assessments flowchart. FFQ: food frequency

255 questionnaire, 24 HR: 24-hour dietary recalls, BP: Blood pressure, H: Height, W: Weight.

256

257

258 2.3. Data Collection, Management and Analysis

259 2.3.1. Data collection

260 *PHASE 1*

261 **Feasibility assessment of FFQ:** The feasibility of the FFQ will be evaluated in a small number
262 of participants (n=75) in a ratio of 2:1 consisting of 50 clinical patients and 25 healthcare
263 professionals to ensure adequate saturation in both groups (**Figure 1**). In the feasibility
264 assessment, eligible clinical patients and healthcare professionals will fill out the questionnaire
265 and be asked to provide feedback on the clarity, ease of use, cultural appropriateness and
266 difficulty encountered in answering the questions. Additionally, the healthcare professionals
267 will provide feedback on the clinical relevance and potential impact on patient care and suggest
268 improvements to optimise the questionnaire's effectiveness. In summary, we will be well-
269 powered to evaluate feasibility from the perspective of patients and clinicians.

270

271 **Validation and Reproducibility of the FFQ:** The FFQ will be administered to clinical patients
272 (n=50) twice (i.e., first and third visits) to quantify the intake of food items. Additionally, an
273 inconsecutive three (3) repeated 24HR, including two weekdays and one weekend day, will be
274 used to collect dietary information from the clinical patients for the past 24 hours using the
275 multiple-pass method (16, 17) at the time of visits and intervals between the two FFQs
276 administrations (**Figure 1**). The reproducibility of the FFQ will be assessed by measuring the
277 level of agreement between the two administrations of the FFQ. Furthermore, the validation
278 will be assessed by evaluating the agreement level between the FFQ and the average of the
279 three 24-hour recalls (27, 28). Healthcare professionals are not involved in the patient FFQ
280 validation stage.

281

282 **Development of FFQ score:** The FFQ score will be developed using the participant's dietary
283 intake captured by the FFQ (**Figure 1**). A three-point scoring system will be developed for
284 each of the food groups - healthy dietary intake (3 points), moderate dietary intake (2 points)
285 and unhealthy dietary habits (1 point) – with participants scored according to their self-reported
286 intake (29, 30). The scoring system will be informed according to existing scientific evidence,
287 dietary guidelines and recommendations, and validation studies (31).

288

289

290

291 ***PHASE 2***

292 ***Acceptability assessment of the FFQ:*** A feasibility trial to test the acceptability of the refined
293 FFQ and gather information on modifications to improve ease of use and future implementation
294 in Nigerian clinics will be conducted (**Figure 1**). The FFQ will be administered to clinical
295 patients (n=50) once to collect their dietary intake and feedback to assess the acceptability of
296 the FFQ. Acceptability will be evaluated by qualitative feedback on indicators of the (i) process
297 (e.g., proportion interested, started, completed FFQ), (ii) resource (e.g., time to complete and
298 review, rated performance on handheld devices), and (iii) data management (e.g., suitability of
299 user interface, data storage and analyses) endpoints(25). Ten questions, 5-item Likert-scale
300 questions, such as “strongly disagree, disagree, neutral, agree, or strongly agree”. The ratings
301 for each of the 10 questions will be used to generate both individual participants’ acceptability
302 ratings as well as an overall acceptability score from all participants.

303

304 ***Assessment of the FFQ score and hypertension risk:*** The refined FFQ will be administered
305 to the clinical patients (n=50) to assess their dietary habits. Individual FFQ scores will be
306 calculated for each clinical patient from their FFQs. A logistic regression will be performed
307 between FFQ scores and hypertension risk (blood pressure), with a correlation coefficient (r)
308 of around 0.5, suggesting a moderate to strong association. The odds ratio will be calculated to
309 quantify the strength of the association between the FFQ score and hypertension.

310

311 ***Non-Dietary Data Collection***

312 In phases 1 and 2, in addition to dietary intake, socioeconomic and demographic data such as
313 gender (sex), age, education, and level of physical activity will be collected using a structured
314 questionnaire from the clinical patients. The blood pressure and anthropometric data (such as
315 weight and height) will be measured using a standard procedure from each clinical patient, and
316 the average will be calculated and used. Body mass index (BMI) will be calculated using weight
317 in kilograms by height in meters squared. Hypertension will be defined as SBP \geq 140mm Hg
318 and DBP \geq 90mm Hg or on antihypertension medication (32).

319

320 **2.3.2. Data Management**

321 Data management, confidentiality, and access in this study will adhere to stringent security
322 measures. All data collected in physical format (such as Questionnaires, including the primary
323 eligibility screening questionnaire, health questionnaires, and Food Frequency Questionnaires
324 (FFQs)) utilised during participant visits will be digitised through scanning. Both electronic
325 and physical copies will be retained, with the latter securely stored within a locked cabinet in
326 the principal investigator's secure office.

327

328 **2.3.3. Statistical Analysis**

329 Statistical analyses will be conducted using R programming language version 4.3.0 (33) with
330 a significance level set at $p < 0.05$. Descriptive statistics will be used to analyse categorical and
331 continuous variables. Categorical demographic variables will be analysed using frequency
332 distribution, while continuous demographic variables will be summarised as mean and standard
333 deviation for normally distributed variables and median and interquartile range (IQR) for non-
334 normally distributed variables. As the frequencies of food groups are not normally distributed,
335 differences in frequencies between the two FFQs (FFQ1 vs. FFQ2) and between the two
336 methods (24 HR vs. FFQ2) in phase 1 will be tested using Wilcoxon's signed-rank test.

337

338 Feasibility and acceptability will be assessed through descriptive analyses, including means
339 and 95% confidence intervals (CI), qualitative feedback, and content analysis of indicators
340 related to the process (e.g., proportion interested, started, completed FFQ) and resource (e.g.,
341 time to complete and review, rated performance, and practicality).

342

343 The West African Food Composition Table will be used to calculate the nutrient content
344 (macronutrients such as energy, carbohydrates or sugar, proteins, fats, and fibre and minerals
345 such as sodium and potassium) of the foods reported in both the FFQ and 24HR. The mean and
346 distribution of nutrient intakes obtained from the FFQ and 24HR will be calculated, and a
347 comparison will be made to assess the differences using the Wilcoxon signed-rank test. Pearson
348 correlations will be used to calculate the correlation coefficients between the FFQ and 24HR
349 for each nutrient to assess the agreement between the FFQs and 24HR and the reproducibility
350 of the FFQs. Additionally, the agreement between the FFQ and the average of three 24-hour
351 dietary recalls will be estimated using Intraclass Correlation Coefficient (ICC) or quintile
352 cross-classification analysis and the Bland-Altman plots will be used to visualise the agreement
353 between the recalls and FFQ (34-36).

354

355 Dietary intake according to the 27-item FFQ will be used to develop an FFQ score based on
356 associations between individual foods and blood pressure using correlation and regression
357 analysis. The result of the regression models will inform the weighting and scoring assignment
358 for each food item in the FFQ. Following the assignment of scores for each individual food
359 item, an aggregation process will be undertaken to obtain an overall dietary score for each
360 participant. The association between the FFQ score and blood pressure will be evaluated using
361 regression analysis, allowing for a robust evaluation of the scoring system's predictive validity
362 and adjusting for potential confounders, such as age, sex, BMI, physical activity, and
363 socioeconomic status.

364

365 **2.4. Monitoring**

366 This study will implement a robust data monitoring plan to ensure the collected data's accuracy,
367 integrity, and confidentiality. Trained research personnel will regularly review and verify the

368 data for completeness and consistency. Additionally, electronic data capture systems will
369 facilitate real-time monitoring and error detection. Any discrepancies or anomalies will be
370 promptly addressed and documented.

371

372 Given the non-interventional nature of this study and the utilisation of non-invasive data
373 collection methods such as the 24-hour dietary recall, the anticipated risks and harms to
374 participants are minimal. However, participants will be informed of any potential discomfort
375 or inconvenience associated with data collection.

376

377 Additionally, measures will be in place to address any unexpected adverse events that may
378 arise during the study. To ensure adherence to established protocols and regulatory guidelines,
379 periodic audits will be conducted by an independent third party. These audits will encompass
380 a comprehensive review of study documentation, data collection procedures, and adherence to
381 ethical standards. Any identified discrepancies or deviations will be addressed promptly, and
382 corrective actions will be implemented to maintain the integrity and validity of the study.

383

384 **2.5. Ethics and Dissemination**

385 **2.5.1. Research Ethics Approval**

386 Ethical approval has been carefully addressed in this study, as evidenced by the approval from
387 the following ethics boards. Business, Earth & Environment, Social Sciences (AREA FREC)
388 Committee, University of Leeds, Leeds, United Kingdom, approved with the number: 0484 on
389 28/04/2023. Similarly, the Rivers State University Teaching Hospital Research Ethics
390 Committee in Port Harcourt, Nigeria, approved with the number: RSUTH/REC/2023316 on
391 30/03/2023. The study prioritises the protection of participants' rights and well-being by
392 upholding key ethical principles. All participants will undergo the informed consent procedure

393 to ensure that all participants will receive comprehensive information about the study's
394 purpose, methods, potential risks, and benefits. All data collected, including questionnaires and
395 personal identifiers, will be treated as confidential. Participants will be assigned unique study
396 IDs, and strict security measures will be implemented.

397

398 **2.5.2. Protocol Amendments**

399 Any proposed amendments to the protocol that could impact the conduct of the study,
400 participant recruitment, participant information dissemination, or data analysis will undergo a
401 thorough evaluation. These modifications will be submitted as amendments to the University
402 of Leeds Research Ethics Committee for approval. Following their approval, the updated
403 protocol details will also be communicated to *ClinicalTrials.gov*. In cases where changes
404 pertain to enrolled participants, they will be promptly informed of the modifications.

405

406 **2.5.3. Consent**

407 Participants who meet the inclusion criteria will be given the Participant Information Sheet
408 (PIS) and an informed consent form to review independently. After 3 days, study personnel
409 will contact the eligible participants by telephone. If they express interest in participating in
410 the study, they will be asked to sign the informed consent and be given a study identification
411 number.

412

413 **2.5.4. Confidentiality and Access to Data**

414 All data collected will be coded to ensure anonymity, and any identifying information will be
415 securely stored separately from the research data. Throughout data collection, a stringent
416 anonymisation process will be implemented. Participants' identities will be safeguarded by
417 recording only their randomisation numbers and dates of birth within the data collection tools.

418 Anonymised data will be treated in accordance with the University of Leeds's Research Data
419 Management Policy, ensuring that sharing, publication, and utilisation are conducted while
420 preserving participant privacy. Any personal, identifiable, or sensitive information will be
421 excluded from publications. Data retention will extend for a minimum of 5 years following
422 publication. Access to the data will be restricted to authorised research team members
423 exclusively.

424

425 **2.5.5. Declaration of Interests**

426 The authors declare no conflicts of interest.

427

428 **2.5.6. Dissemination Plans**

429 The results from this study will be disseminated promptly through various channels to ensure
430 wide accessibility and impact. First, a manuscript detailing the research methodology, results,
431 and conclusions in both phase 1 and phase 2 will be prepared for submission for publication in
432 open-access, peer-reviewed scientific journals. Secondly, presentations will be made at
433 relevant national and international scientific conferences, allowing for engagement with
434 experts in the field and the broader research community. In addition, the results will be
435 summarised in accessible and easy-to-use formats for dissemination to healthcare
436 professionals, policymakers, and the public in Nigeria. Infographics, fact sheets, and webinars
437 will be developed to convey key findings and practical implications for hypertension
438 prevention strategies. The entire protocol, the anonymised dataset and any relevant statistical
439 code will be deposited in the Leeds Research Data Repository and available open access.

440

441 **2.6. Discussion**

442 Unhealthy dietary shifts from whole foods to highly processed ‘fast food’ options have been
443 linked to the escalating hypertension prevalence in Nigeria. Notably, dietary habits are
444 evolving, marked by increased consumption of meals from eateries and fast-food vendors
445 offering high-fat, high-salt, and high-sugar processed foods (1, 8, 9). Positive outcomes in
446 hypertension and cardiovascular health have been noted through dietary and lifestyle changes
447 (37-40). Hence, responsive short dietary assessment tools can swiftly guide healthcare
448 professionals in pinpointing concerns and establishing and tracking dietary goals for patients,
449 including patients with hypertension (41, 42). Several tools exist for dietary management of
450 cardiovascular disease, type 2 diabetes, hypertension, and non-alcoholic fatty liver disease
451 (NAFLD) that have successfully been developed for clinical use (27, 41, 42). Nevertheless,
452 many of these tools have been designed and validated primarily in the US and Western
453 European nations, limiting their applicability to Nigeria. Our primary aim is to explore the
454 feasibility, validation, and acceptability of a short dietary assessment tool for evaluating dietary
455 intake among individuals with hypertension in Nigeria.

456

457 Currently, no short dietary assessment tool responsive to dietary changes has been developed
458 for hypertensive patients and incorporated into clinical care for the prevention and management
459 of patients with hypertension in Nigeria. Given the practicality of FFQs in settings lacking
460 formal dietetic support and their inherent inclusion of portion sizes to minimise measurement
461 error [15], our aim is to validate a developed short FFQ. The developed FFQ will be informed
462 by the findings of Batubo et al. (8) and the Nigeria Nutritional Guidelines (10) culminated in a
463 27-item tool designed for use with hypertensive patients. We aim to investigate the relative
464 validity of our newly developed short FFQ in relation to 24-hour dietary recall from 50 clinical
465 patients focusing on commonly consumed food in Nigeria. This approach to validate the FFQ
466 has been extensively utilised in the literature by previous studies (27, 29, 43-45).

467

468 Feedback from clinical patients and healthcare professionals regarding the FFQ's feasibility is
469 expected to drive its refinement within a user-friendly clinical context. This could potentially
470 bridge the gap between nutritional guidelines and clinical care, equipping healthcare
471 professionals to systematically assess the dietary intake of patients for diagnostic and
472 preventive purposes and enable clinicians to provide region-specific dietary recommendations,
473 fostering improved disease prevention and management, including hypertension (46). The
474 anticipated findings from the Intraclass Correlation Coefficient (ICC) analysis and correlations
475 between the FFQ and 24-hour dietary recall (24HR) are poised to illuminate the FFQ's
476 reproducibility and validity in assessing dietary intake. Strong ICC values and correlations
477 above 0.4 would indicate the FFQ's reliability and accuracy in capturing habitual dietary
478 patterns, which is crucial for providing accurate dietary advice to patients (42, 47, 48). The
479 scoring system for the FFQ could offer a practical means of categorising habitual dietary habits.
480 Should the scoring system align with established dietary recommendations and scientific
481 evidence, it could be a valuable tool for clinicians to assess dietary quality and offer tailored
482 dietary guidance to patients. The assessment of the acceptability of the FFQ. Positive feedback
483 could indicate that the FFQ is well-received by clinical patients and that its implementation
484 could be feasible in a clinical setting. This information is essential for potentially integrating
485 the FFQ into routine clinical practice.

486

487 This study protocol presents several notable strengths. Firstly, the study addresses a critical gap
488 in the rising challenge of hypertension in Nigeria and the lack of a short dietary tool that can
489 be incorporated into clinical care by focusing on the feasibility, validity, and acceptability of a
490 dietary assessment tool explicitly tailored to Nigeria. Secondly, the inclusion of both clinical
491 patients and healthcare professionals in the feasibility assessment phase ensures comprehensive

492 feedback from both user groups, enhancing the applicability and relevance of the dietary
493 assessment tool. The limitations of this work include the use of a sole patient cohort and the
494 risk of selection bias, which means that the results may not be generalised to other populations
495 or settings beyond the selected clinical outpatient. Furthermore, reliance on self-reported
496 dietary data through FFQs and 24-hour recalls introduces potential recall bias and measurement
497 error, which may impact the accuracy of dietary assessments (49, 50).

498

499 **Acknowledgements**

500 Not applicable

501

502

503

504

505

506

507

508

509

510

511

512

513

514

515

516

517

518

519

520

521

522 References

523

- 524 1. Mills KT, Bundy JD, Kelly TN, Reed JE, Kearney PM, Reynolds K, et al. Global
525 Disparities of Hypertension Prevalence and Control: A Systematic Analysis of Population-
526 Based Studies From 90 Countries. *Circulation*. 2016;134(6):441-50.
- 527 2. WHO. Hypertension Factsheet. World Health Organization 2021 [Available from:
528 <https://www.who.int/news-room/fact-sheets/detail/hypertension>.
- 529 3. Ferdinand KC. Uncontrolled hypertension in sub-Saharan Africa: Now is the time to
530 address a looming crisis. *J Clin Hypertens (Greenwich)*. 2020;22(11):2111-3.
- 531 4. WHO. Global Health Observatory. Prevalence of hypertension among adults aged 30-
532 79 years 2022 [Available from: [https://www.who.int/data/gho/data/indicators/indicator-](https://www.who.int/data/gho/data/indicators/indicator-details/gho/prevalence-of-hypertension-among-adults-aged-30-79-years)
533 [details/gho/prevalence-of-hypertension-among-adults-aged-30-79-years](https://www.who.int/data/gho/data/indicators/indicator-details/gho/prevalence-of-hypertension-among-adults-aged-30-79-years).
- 534 5. Zhang M, Shi Y, Zhou B, Huang Z, Zhao Z, Li C, et al. Prevalence, awareness,
535 treatment, and control of hypertension in China, 2004-18: findings from six rounds of a
536 national survey. *BMJ*. 2023;380:e071952.
- 537 6. Ostchega Y, Fryar CD, Nwankwo T, Nguyen DT. Hypertension Prevalence Among
538 Adults Aged 18 and Over: United States, 2017-2018. *NCHS Data Brief*. 2020(364):1-8.
- 539 7. Conor Stewart. Prevalence of adults who have hypertension in England from 2003 to
540 2019, by gender 2022 [Available from:
541 [https://www.statista.com/statistics/1124955/hypertension-prevalence-by-gender-in-](https://www.statista.com/statistics/1124955/hypertension-prevalence-by-gender-in-england-uk/)
542 [england-uk/](https://www.statista.com/statistics/1124955/hypertension-prevalence-by-gender-in-england-uk/).
- 543 8. Batubo NP, Moore JB, Zulyniak MA. Dietary factors and hypertension risk in West
544 Africa: a systematic review and meta-analysis of observational studies. *J Hypertens*.
545 2023;41(9):1376-88.
- 546 9. Petrikova I, Bhattacharjee R, Fraser PD. The 'Nigerian Diet' and Its Evolution: Review
547 of the Existing Literature and Household Survey Data. *Foods*. 2023;12(3).
- 548 10. Federal Ministry of Health. National Nutritional Guideline On Non-Communicable
549 Disease Prevention, Control and Management In: Federal Ministry of Health A, editor. 2014.
550 p. 62.
- 551 11. Bailey RL. Overview of dietary assessment methods for measuring intakes of foods,
552 beverages, and dietary supplements in research studies. *Curr Opin Biotechnol*. 2021;70:91-
553 6.
- 554 12. Shim JS, Oh K, Kim HC. Dietary assessment methods in epidemiologic studies.
555 *Epidemiol Health*. 2014;36:e2014009.
- 556 13. Willett W. Food Frequency Questionnaire. *Nutritional Epidemiology*. Oxford, UK:
557 Oxford University Press; 2013. p. 70-92.
- 558 14. Vasiloglou MF, Fletcher J, Poulia KA. Challenges and Perspectives in Nutritional
559 Counselling and Nursing: A Narrative Review. *J Clin Med*. 2019;8(9).
- 560 15. Holmes B, Dick K, Nelson M. A comparison of four dietary assessment methods in
561 materially deprived households in England. *Public Health Nutr*. 2008;11(5):444-56.
- 562 16. U.S. Department of Agriculture. AMPM - USDA Automated Multiple-Pass Method 6
563 July, 2021 [Available from: [https://www.ars.usda.gov/northeast-area/beltsville-md-](https://www.ars.usda.gov/northeast-area/beltsville-md-bhnrc/beltsville-human-nutrition-research-center/food-surveys-research-group/docs/ampm-usda-automated-multiple-pass-method/)
564 [bhnrc/beltsville-human-nutrition-research-center/food-surveys-research-](https://www.ars.usda.gov/northeast-area/beltsville-md-bhnrc/beltsville-human-nutrition-research-center/food-surveys-research-group/docs/ampm-usda-automated-multiple-pass-method/)
565 [group/docs/ampm-usda-automated-multiple-pass-method/](https://www.ars.usda.gov/northeast-area/beltsville-md-bhnrc/beltsville-human-nutrition-research-center/food-surveys-research-group/docs/ampm-usda-automated-multiple-pass-method/).

- 566 17. Blanton CA, Moshfegh AJ, Baer DJ, Kretsch MJ. The USDA Automated Multiple-Pass
567 Method accurately estimates group total energy and nutrient intake. *J Nutr*.
568 2006;136(10):2594-9.
- 569 18. Willett W. Foreword. The validity of dietary assessment methods for use in
570 epidemiologic studies. *Br J Nutr*. 2009;102 Suppl 1:S1-2.
- 571 19. Adebamowo SN, Eseyin O, Yilme S, Adeyemi D, Willett WC, Hu FB, et al. A Mixed-
572 Methods Study on Acceptability, Tolerability, and Substitution of Brown Rice for White Rice
573 to Lower Blood Glucose Levels among Nigerian Adults. *Front Nutr*. 2017;4:33.
- 574 20. Steinemann N, Grize L, Ziesemer K, Kauf P, Probst-Hensch N, Brombach C. Relative
575 validation of a food frequency questionnaire to estimate food intake in an adult population.
576 *Food Nutr Res*. 2017;61(1):1305193.
- 577 21. Mertens E, Kuijsten A, Geleijnse JM, Boshuizen HC, Feskens EJM, Van't Veer P. FFQ
578 versus repeated 24-h recalls for estimating diet-related environmental impact. *Nutr J*.
579 2019;18(1):2.
- 580 22. Swinscow T.D.V. MJCMJ. Statistics at Square One. Correlation and regression BMJ
581 [19:[Available from: [https://www.bmj.com/about-bmj/resources-
582 readers/publications/statistics-square-one/11-correlation-and-regression](https://www.bmj.com/about-bmj/resources-readers/publications/statistics-square-one/11-correlation-and-regression).
583 23. Faul F, Erdfelder E, Buchner A, Lang AG. Statistical power analyses using G*Power
584 3.1: tests for correlation and regression analyses. *Behav Res Methods*. 2009;41(4):1149-60.
- 585 24. Hennink M, Kaiser BN. Sample sizes for saturation in qualitative research: A
586 systematic review of empirical tests. *Soc Sci Med*. 2022;292:114523.
- 587 25. Thabane L, Ma J, Chu R, Cheng J, Ismaila A, Rios LP, et al. A tutorial on pilot studies:
588 the what, why and how. *BMC Med Res Methodol*. 2010;10:1.
- 589 26. Gupta KK, Attri JP, Singh A, Kaur H, Kaur G. Basic concepts for sample size
590 calculation: Critical step for any clinical trials! *Saudi J Anaesth*. 2016;10(3):328-31.
- 591 27. Rossato SL, Mosele F, Moreira LB, Rodrigues MP, Lima RF, Fuchs FD, et al.
592 Development, Validation, and Reproducibility of Food Group-Based Frequency
593 Questionnaires for Clinical Use in Brazil: A Pre-Hypertension and Hypertension Diet
594 Assessment. *Nutrients*. 2021;13(11).
- 595 28. Yuan MY, He JR, Chen NN, Lu JH, Shen SY, Xiao WQ, et al. Validity and Reproducibility
596 of a Dietary Questionnaire for Consumption Frequencies of Foods during Pregnancy in the
597 Born in Guangzhou Cohort Study (BIGCS). *Nutrients*. 2016;8(8).
- 598 29. Cleghorn CL, Harrison RA, Ransley JK, Wilkinson S, Thomas J, Cade JE. Can a dietary
599 quality score derived from a short-form FFQ assess dietary quality in UK adult population
600 surveys? *Public Health Nutr*. 2016;19(16):2915-23.
- 601 30. Toft U, Kristoffersen LH, Lau C, Borch-Johnsen K, Jorgensen T. The Dietary Quality
602 Score: validation and association with cardiovascular risk factors: the Inter99 study. *Eur J
603 Clin Nutr*. 2007;61(2):270-8.
- 604 31. Kant AK, Thompson FE. Measures of overall diet quality from a food frequency
605 questionnaire: National Health Interview Survey. *Nutrition Research*. 1997;17:1443-56.
- 606 32. Dolan E, Stanton A, Atkins N, Den Hond E, Thijs L, McCormack P, et al. Determinants
607 of white-coat hypertension. *Blood Press Monit*. 2004;9(6):307-9.
- 608 33. R Core Team. A language and environment for statistical computing. R Foundation
609 for Statistical Computing. 4.1.3 ed: Vienna, Austria; 2020.
- 610 34. Marques-Vidal P, Ross A, Wynn E, Rezzi S, Paccaud F, Decarli B. Reproducibility and
611 relative validity of a food-frequency questionnaire for French-speaking Swiss adults. *Food
612 Nutr Res*. 2011;55.

- 613 35. Wong JE, Parnell WR, Black KE, Skidmore PM. Reliability and relative validity of a
614 food frequency questionnaire to assess food group intakes in New Zealand adolescents.
615 *Nutr J.* 2012;11:65.
- 616 36. Bland JM, Altman DG. Measuring agreement in method comparison studies. *Stat*
617 *Methods Med Res.* 1999;8(2):135-60.
- 618 37. Appel LJ, Moore TJ, Obarzanek E, Vollmer WM, Svetkey LP, Sacks FM, et al. A clinical
619 trial of the effects of dietary patterns on blood pressure. *New England journal of medicine.*
620 1997;336(16):1117-24.
- 621 38. Sacks FM, Svetkey LP, Vollmer WM, Appel LJ, Bray GA, Harsha D, et al. Effects on
622 blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension
623 (DASH) diet. *New England journal of medicine.* 2001;344(1):3-10.
- 624 39. Juraschek SP, Miller ER, 3rd, Weaver CM, Appel LJ. Effects of Sodium Reduction and
625 the DASH Diet in Relation to Baseline Blood Pressure. *J Am Coll Cardiol.* 2017;70(23):2841-8.
- 626 40. Vinceti M, Filippini T, Crippa A, de Sesmaisons A, Wise LA, Orsini N. Meta-Analysis of
627 Potassium Intake and the Risk of Stroke. *J Am Heart Assoc.* 2016;5(10).
- 628 41. England CY, Andrews RC, Jago R, Thompson JL. A systematic review of brief dietary
629 questionnaires suitable for clinical use in the prevention and management of obesity,
630 cardiovascular disease and type 2 diabetes. *Eur J Clin Nutr.* 2015;69(9):977-1003.
- 631 42. Bredin C, Naimimohasses S, Norris S, Wright C, Hancock N, Hart K, et al.
632 Development and relative validation of a short food frequency questionnaire for assessing
633 dietary intakes of non-alcoholic fatty liver disease patients. *Eur J Nutr.* 2020;59(2):571-80.
- 634 43. Yan N, Li N, Liu W, Li X, Liu X, Zhang P, et al. Validity and reliability of a semi-
635 quantitative food frequency questionnaire in groups at high risk for cardiovascular diseases.
636 *Nutr J.* 2022;21(1):63.
- 637 44. Freedman LS, Midthune D, Arab L, Prentice RL, Subar AF, Willett W, et al. Combining
638 a Food Frequency Questionnaire With 24-Hour Recalls to Increase the Precision of
639 Estimation of Usual Dietary Intakes-Evidence From the Validation Studies Pooling Project.
640 *Am J Epidemiol.* 2018;187(10):2227-32.
- 641 45. Collese TS, De Moraes ACF, Rendo-Urteaga T, Gonzalez-Zapata LI, Charry DAG,
642 Delgado CA, et al. Evaluation of the Validity of a Food Frequency Questionnaire and 24-Hour
643 Dietary Recall to Assess Dietary Iron Intake in Children and Adolescents from the South
644 American Youth/Child Cardiovascular and Environmental Study. *J Acad Nutr Diet.*
645 2022;122(2):384-93.
- 646 46. Reber E, Gomes F, Vasiloglou MF, Schuetz P, Stanga Z. Nutritional Risk Screening and
647 Assessment. *J Clin Med.* 2019;8(7).
- 648 47. Noor Hafizah Y, Ang LC, Yap F, Nurul Najwa W, Cheah WL, Ruzita AT, et al. Validity
649 and Reliability of a Food Frequency Questionnaire (FFQ) to Assess Dietary Intake of
650 Preschool Children. *Int J Environ Res Public Health.* 2019;16(23).
- 651 48. Dehghan M, Martinez S, Zhang X, Seron P, Lanas F, Islam S, et al. Relative validity of
652 an FFQ to estimate daily food and nutrient intakes for Chilean adults. *Public Health Nutr.*
653 2013;16(10):1782-8.
- 654 49. Naska A, Lagiou A, Lagiou P. Dietary assessment methods in epidemiological
655 research: current state of the art and future prospects. *F1000Res.* 2017;6:926.
- 656 50. Gibson RS, Charrondiere UR, Bell W. Measurement Errors in Dietary Assessment
657 Using Self-Reported 24-Hour Recalls in Low-Income Countries and Strategies for Their
658 Prevention. *Adv Nutr.* 2017;8(6):980-91.
- 659

660

661

662

663 **Supporting Information**

664 SPIRIT Checklist for the Protocol

665 Informed consent material

SPIRIT 2013 Checklist: Dietary Assessment and Prevention of Hypertension in Nigeria: Protocol for a Retrospective Cross-sectional Study for the Development and Validation of a Food Frequency Questionnaire for Clinical Use.

Section/item	Item No	Description	Addressed on page number
Administrative information			
Title	1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	1
Trial registration	2a	Trial identifier and registry name. If not yet registered, name of intended registry	1
	2b	All items from the World Health Organization Trial Registration Data Set	
Protocol version	3	Date and version identifier	1
Funding	4	Sources and types of financial, material, and other support	1
Roles and responsibilities	5a	Names, affiliations, and roles of protocol contributors	1
	5b	Name and contact information for the trial sponsor	1
	5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	NA

	5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)	NA
--	----	--	----

Introduction

Background and rationale	6a	Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention	3
	6b	Explanation for choice of comparators	3
Objectives	7	Specific objectives or hypotheses	5
Trial design	8	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory)	5

Methods: Participants, interventions, and outcomes

Study setting	9	Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained	6
Eligibility criteria	10	Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists)	6
Interventions	11a	Interventions for each group with sufficient detail to allow replication, including how and when they will be administered	6
	11b	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving/worsening disease)	NA
	11c	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return, laboratory tests)	NA
	11d	Relevant concomitant care and interventions that are permitted or prohibited during the trial	NA

Outcomes	12	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended	7
Participant timeline	13	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure)	8
Sample size	14	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations	10
Recruitment	15	Strategies for achieving adequate participant enrolment to reach target sample size	10

Methods: Assignment of interventions (for controlled trials)

Allocation:

Sequence generation	16a	Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions	11
Allocation concealment mechanism	16b	Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned	NA
Implementation	16c	Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions	NA
Blinding (masking)	17a	Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and how	NA
	17b	If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's allocated intervention during the trial	NA

Methods: Data collection, management, and analysis

Data collection methods	18a	Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol	13
	18b	Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols	13
Data management	19	Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol	14
Statistical methods	20a	Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol	14
	20b	Methods for any additional analyses (eg, subgroup and adjusted analyses)	14
	20c	Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation)	14
Methods: Monitoring			
Data monitoring	21a	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed	16
	21b	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial	16
Harms	22	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct	16
Auditing	23	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor	16

Ethics and dissemination

Research ethics approval	24	Plans for seeking research ethics committee/institutional review board (REC/IRB) approval	16
Protocol amendments	25	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, regulators)	17
Consent or assent	26a	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)	17
	26b	Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable	NA
Confidentiality	27	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial	18
Declaration of interests	28	Financial and other competing interests for principal investigators for the overall trial and each study site	18
Access to data	29	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators	18
Ancillary and post-trial care	30	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation	NA
Dissemination policy	31a	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions	18
	31b	Authorship eligibility guidelines and any intended use of professional writers	NA
	31c	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code	17
Appendices			
Informed consent materials	32	Model consent form and other related documentation given to participants and authorised surrogates	

Biological specimens	33	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable
----------------------	----	--

NA: Not applicable